U.S. market Closed. Opens in 1 day 5 hours 11 minutes

CNTA | Centessa Pharmaceuticals plc Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue6.85MN/AN/AN/AN/A
Cost of RevenueN/A130.92K33.99KN/AN/A
Gross Profit6.85M-130.92K-33.99KN/AN/A
Operating Expenses178.14M210.28M139.28M10.44M5.05M
Selling, General & Admin53.73M55.20M42.97M1.14M790.00K
Research & Development124.41M155.08M96.31M9.30M4.26M
Other Operating ExpensesN/A2.34MN/A155.00K105.00K
Operating Income-171.28M-212.26M-139.31M-10.44M-5.05M
Other Expenses / Income-4.86M-4.69M-6.87M-223.00K-8.00K
Before Tax Income-176.14M-216.95M-381.74M-10.66M-5.06M
Income Tax Expenses-25.06M-747.00K113.99K378.00K223.00K
Net Income-151.09M-216.21M-381.85M-11.04M-5.28M
Interest Expenses9.91M7.03M2.55M378.00K118.00K
Basic Shares Outstanding96.18M93.40M89.99M142.06M70.89M
Diluted Shares Outstanding96.18M93.40M89.99M142.06M70.89M
EBITDA-166.07M-212.26M-379.16M-10.43M-4.94M
EBITDA Margin-2,423.26%0.00%0.00%0.00%0.00%
EBIT-166.24M-209.92M-379.19M-10.29M-4.94M
EBIT Margin-2,425.73%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙